Condition: Lymphoblastic Leukemia · Relapsed or Refractory Multiple Myeloma (RRMM) · Sponsor: Anhui Provincial Hospital
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
This description comes directly from the study's public registry record.
bing xing wang, M.D · 860551-62284476 · wangxingbing@ustc.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of University of Science and Technology of China | Hefei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06961669